Bruce Benge, MD
Urology · Wilmington, DENPI 1558319145
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,177 of the $4,587 with a category attached, or 69.3%. 31 manufacturers reported payments, led by Neotract Inc. at 27.8% of the total.
Across 134 payments — averaging $34.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$1K
- EMD Serono, Inc.$726
- Urogen Pharma, Inc.$342
- Sumitomo Pharma America, Inc.$322
- Bayer$275
- Astellas Pharma US Inc$267
- plus $1K from 25 others
What the payments were for
- Travel & lodging$1,23127%
- Food & beverage$3,17769%
- Education$1794%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 7 | $1,275 |
| EMD Serono, Inc. | 2 | $726 |
| Urogen Pharma, Inc. | 16 | $342 |
| Sumitomo Pharma America, Inc. | 22 | $322 |
| Bayer | 13 | $275 |
| Astellas Pharma US Inc | 9 | $267 |
| Johnson & Johnson(2 entities) | 8 | $185 |
| Pfizer | 4 | $170 |
| AbbVie(2 entities) | 6 | $130 |
| Accord Healthcare, Inc. | 5 | $91 |
| Merck | 4 | $88 |
| Myriad Genetic Laboratories, Inc. | 5 | $75 |
| Tolmar, Inc. | 3 | $64 |
| Antares Pharma, Inc. | 4 | $63 |
| Ferring Pharmaceuticals Inc. | 3 | $54 |
| Axonics, Inc. | 2 | $48 |
| Dendreon Pharmaceuticals LLC | 2 | $47 |
| Myovant Sciences Inc. | 2 | $44 |
| Dentsply IH AB | 1 | $43 |
| Progenics Pharmaceuticals, Inc. | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Tolmar Pharmaceuticals, Inc. | 2 | $31 |
| Mission Pharmacal Company | 2 | $31 |
| Tempus AI, Inc | 1 | $29 |
| Civco Medical Instruments | 1 | $26 |
| Amgen | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $16 |
| AstraZeneca | 1 | $16 |
| Clovis Oncology, Inc. | 1 | $14 |
| Endo USA, Inc. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,587 in reported general payments places this provider in the 75th percentile of 33 urology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 38 | $571,161 |
| OrgovyxRelugolix | 65 | $236,966 |
| MyrbetriqMirabegron | 122 | $110,471 |
| GemtesaVibegron | 48 | $38,751 |
| Tamsulosin Hcl | 1,487 | $29,852 |
| Abiraterone Acetate | 13 | $29,208 |
| ElmironPentosan Polysulfate Sodium | 12 | $26,148 |
| Finasteride | 587 | $11,284 |
| Tolterodine Tartrate ErTolterodine Tartrate | 42 | $5,947 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 284 | $3,381 |
| Potassium Citrate ErPotassium Citrate | 24 | $2,887 |
| Testosterone | 12 | $2,614 |
| Dutasteride | 19 | $1,692 |
| Doxazosin Mesylate | 95 | $1,676 |
| Oxybutynin Chloride ErOxybutynin Chloride | 59 | $1,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $267 | $681,632160 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $322 | $275,717113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 33 urology providers in Delaware.
Other urology in Wilmington
- Christopher MitchellWilmington$19K
- Michael LobisWilmington$8K
- Thomas DesperitoWilmington$7K
- Alice WangWilmington$4K
- Keara DecotiisWilmington$3K
- Mohamed IsmailWilmington$3K
- David CozzolinoWilmington$2K
- Mona YezdaniWilmington$2K
- Steven TerranovaWilmington$2K
- Andrew GlickWilmington$748
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.